Cipla Ltd.

NSE: CIPLA BSE: 500087 SECTOR: Pharmaceuticals & Drugs  164k   2k   285

894.95
-17.10 (-1.87%)
NSE: 06 Dec 04:09 PM

Price Summary

Today's High

₹ 915.8

Today's Low

₹ 892.5

52 Week High

₹ 1005

52 Week Low

₹ 738.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

72203.39 Cr.

Enterprise Value

71328.59 Cr.

No. of Shares

80.68 Cr.

P/E

26.88

P/B

3.42

Face Value

₹ 2

Div. Yield

0.56 %

Book Value (TTM)

₹  261.9

CASH

874.8 Cr.

DEBT

0 Cr.

Promoter Holding

36.12 %

EPS (TTM)

₹  33.3

Sales Growth

9.81%

ROE

13.25 %

ROCE

18.19%

Profit Growth

6.48 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Cipla Ltd.

Dytor Moxicip Novamox Lametec Ibugesic Fourderm CPink CDense Productiv nicotex ActivKids immuno boosters cofsils CIPHANDS OMNIGEL CORYX BRONCOL COUGH SYRUP Cheston

Index Presence

The company is present in 30 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.81%
3 Year6.87%
5 Year3.07%

Profit Growth

1 Year6.48%
3 Year18.9%
5 Year11.04%

ROE%

1 Year13.25%
3 Year13.31%
5 Year11.76%

ROCE %

1 Year18.19%
3 Year17.65%
5 Year15.27%

Debt/Equity

0

Price to Cash Flow

20.87

Interest Cover Ratio

75.3434657199911

CFO/PAT (5 Yr. Avg.)

1.12635002939138

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 36.12 0
Jun 2021 36.72 0
Mar 2021 36.73 0
Dec 2020 36.7 0
Sep 2020 36.7 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 18.8971705214892% for the Past 3 years.
  • The company has significantly decreased its debt by 6.06 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 75.3434657199911.
  • Company has a healthy liquidity position with current ratio of 3.78618394169261.
  • The company has a good cash flow management; CFO/PAT stands at 1.12635002939138.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.45174683911559.

 Limitations

  • The company has shown a poor revenue growth of 6.86553643431116% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 3807.89 3731.55 3233.12 4017.41 3935.03
Total Expenditure 2676.92 2735.4 2583.42 2871.92 2952.21
Operating Profit 1130.97 996.15 649.7 1145.49 982.82
Other Income 39.17 96.12 49.33 79.66 197.73
Interest 11.69 10.33 8.84 8 7.6
Depreciation 140.8 134.57 137.01 136.98 138.97
Exceptional Items 0 0 0 0 0
Profit Before Tax 1017.65 947.37 553.18 1080.17 1033.98
Tax 272.01 248.44 139.77 288.4 251.61
Profit After Tax 745.64 698.93 413.41 791.77 782.37
Adjusted EPS (Rs) 9.25 8.67 5.13 9.82 9.7

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 10768.49 11389.9 12374.01 12659.15 13900.58
Total Expenditure 9172.23 9194.35 9879.69 9991.76 10192.05
Operating Profit 1596.26 2195.55 2494.32 2667.39 3708.53
Other Income 129.85 334.88 577.52 913.76 230.28
Interest 39.2 11.9 16.97 36.05 45.07
Depreciation 499.97 529.61 562.04 580.79 543.08
Exceptional Items 0 -77.52 0 0 0
Profit Before Tax 1186.94 1911.4 2492.83 2964.31 3350.66
Tax 212 442.88 604.42 646.14 882.38
Net Profit 974.94 1468.52 1888.41 2318.17 2468.28
Adjusted EPS (Rs.) 12.12 18.24 23.44 28.75 30.61

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 160.9 161.02 161.14 161.25 161.29
Total Reserves 12639.61 13952.5 15620.77 17241.71 19766.27
Borrowings 0.07 0 0 0 0
Other N/C liabilities 191.27 202.95 268.82 383.41 344.24
Current liabilities 2555.83 2731.7 2368.08 2619.29 2691.94
Total Liabilities 15547.68 17048.17 18418.81 20405.66 22963.74
Assets
Net Block 4235.26 4320.03 4127.46 4024.54 3942.66
Capital WIP 540.52 435.28 241.32 255.73 275.04
Intangible WIP 15.25 27.32 56.01 64 80.07
Investments 3648.03 3597.56 3865.46 6481.76 7844.78
Loans & Advances 624.98 611.43 583.23 516.63 596.1
Other N/C Assets 138.3 118.38 66.68 35.94 32.91
Current Assets 6345.34 7938.17 9478.65 9027.06 10192.18
Total Assets 15547.68 17048.17 18418.81 20405.66 22963.74
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 1186.94 1911.4 2492.83 2964.31 3350.66
Adjustment 778.6 315.64 187.6 -35.73 511.27
Changes in Assets & Liabilities 573.12 -588 -761 -245.46 550.33
Tax Paid -331.27 -522.51 -451.38 -664.98 -951.95
Operating Cash Flow 2207.39 1116.53 1468.05 2018.14 3460.31
Investing Cash Flow -1191.75 -592.72 -1147.71 -1127.18 -3361.33
Financing Cash Flow -1010.8 -350.96 -473.32 -693.89 -65.8
Net Cash Flow 4.84 172.85 -152.98 197.07 33.18

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 36.70 36.70 36.73 36.72 36.12
yusuf khwaja hamied 20.36 20.36 20.36 20.35 20.35
sophie ahmed 5.71 5.71 5.71 5.71 5.71
mustafa khwaja ham... 4.29 4.29 4.29 4.29 4.29
samina vaziralli 2.22 2.22 - 2.22 -
samina hamied - - 2.22 - 2.22
kamil hamied 1.36 1.36 1.36 1.36 1.36
rumana hamied 1.23 1.23 1.23 1.23 1.23
shirin hamied 0.79 0.79 0.79 0.79 0.79
mn rajkumar garmen... 0.67 0.67 0.67 0.67 0.67
alps remedies pvt ... 0.06 0.06 - 0.06 -
alps remedies priv... - - - - 0.06
alps remedies priv... - - 0.06 - -
okasa pharma priva... - - 0.02 - -
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 63.30 63.30 63.27 63.28 63.88
icici prudential m... 5.54 3.99 1.68 5.99 6.29
life insurance cor... 3.49 3.49 2.27 3.74 4.91
sbi mutual fund 1.47 1.14 3.45 1.66 2.09
first state invest... - 3.13 - - -
first state invest... 3.13 - - - -
hdfc mutual fund 2.54 2.53 1.19 3.08 3.05
aditya birla mutua... - - - 1.95 2.44
government pension... 1.22 1.22 2.36 1.16 1.55
reliance mutual fu... 1.46 1.77 - 1.71 -
first state invest... - - - 1.65 -
first state invest... 1.32 - - - -
nps trust - - 1.51 - 1.09
first state invest... - 1.36 - - -
icici prudential l... - - - - -
uti - - - - 1.08
axis mutual fund - - - - -
icici prudential l... - - 0.93 - -
iepf 0.38 0.47 0.39 0.40 0.40

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Cipla informs about analyst meet 24 Nov 2021, 2:14PM Cipla informs about press release17 Nov 2021, 9:50AM Cipla launches 'Spirofy' on World COPD Day17 Nov 2021, 9:05AM Cipla selected in S&P Dow Jones Sustainability Index for Emerging Markets for 202116 Nov 2021, 9:58AM Cipla reports 7% rise in Q2 consolidated net profit27 Oct 2021, 12:36PM Cipla, Eli Lilly and Company enter into strategic partnership in India4 Oct 2021, 11:41AM Cipla informs about issuance of duplicate certificate22 Sep 2021, 4:53PM Cipla subscribes 5% stake in Swasth Digital Health Foundation20 Sep 2021, 12:25PM Cipla informs about analyst meet18 Sep 2021, 4:53PM Cipla informs about analyst meet30 Aug 2021, 3:02PM Cipla informs about voting results and combined scrutinizer’s report of AGM26 Aug 2021, 9:41AM Cipla informs about outcome of AGM26 Aug 2021, 9:24AM Cipla informs about press release25 Aug 2021, 4:43PM Cipla enters into joint venture agreement with Kemwell Biopharma25 Aug 2021, 3:57PM Cipla informs about press release12 Aug 2021, 10:04AM Cipla gets USFDA’s final approval for Difluprednate Ophthalmic Emulsion 12 Aug 2021, 9:17AM Cipla informs about loss of share certificate7 Aug 2021, 11:49AM Cipla reports 24% rise in Q1 consolidated net profit6 Aug 2021, 12:27PM Cipla informs about newspaper advertisements3 Aug 2021, 10:13AM Cipla informs about notice of AGM2 Aug 2021, 12:56PM Cipla informs about conference call28 Jul 2021, 3:59PM Cipla recalls 7,228 bottles of Solifenacin Succinate tablets26 Jul 2021, 9:57AM Cipla informs about allotment of equity shares under ESOP 17 Jul 2021, 12:31PM Cipla, Dr. Reddy’s, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of Molnupiravir for COVID-19 30 Jun 2021, 1:00PM Cipla gets approval to import Moderna's COVID-19 vaccine in India29 Jun 2021, 5:01PM Cipla informs about schedule of investor meet26 Jun 2021, 3:46PM Cipla informs about analyst meet23 Jun 2021, 11:48AM Cipla gets final approval for Arformoterol Tartrate Inhalation Solution23 Jun 2021, 11:31AM Cipla informs about press release15 Jun 2021, 10:03AM Cipla’s step-down associate company receives complete response letter from USFDA for IV Tramadol 15 Jun 2021, 9:32AM Cipla informs about analyst meet7 Jun 2021, 10:07AM Cipla informs about response to media query1 Jun 2021, 10:06AM Cipla informs about analyst meet26 May 2021, 4:01PM Cipla informs about press release24 May 2021, 9:57AM Cipla informs about press release20 May 2021, 9:48AM Cipla launches RT-PCR test kit ‘ViraGen’ for COVID-19 in India20 May 2021, 9:07AM Cipla informs about earnings call transcript18 May 2021, 5:29PM Cipla reports 68% rise in Q4 consolidated net profit15 May 2021, 9:20AM Cipla signs licensing agreement with Eli Lilly 10 May 2021, 10:47AM Cipla informs about press release10 May 2021, 9:48AM Cipla informs about updates4 May 2021, 11:49AM Cipla’s associate company incorporates wholly-owned subsidiary4 May 2021, 9:25AM Cipla enters into licensing agreement with MSD 28 Apr 2021, 3:43PM Cipla informs about postal ballot notice24 Apr 2021, 2:02PM Cipla doubles Remdesivir production to meet 'unprecedented' demand13 Apr 2021, 4:34PM Cipla enters into agreement to become partner in ABCD Technologies LLP31 Mar 2021, 1:37PM Cipla’s affiliate enters into strategic partnership with SIGA Technologies 23 Mar 2021, 9:15AM Cipla pledges support to ‘Terra Carta’ for sustainable future19 Mar 2021, 9:39AM Cipla informs about analyst meet8 Mar 2021, 12:14PM Cipla voluntarily liquidates wholly-owned step-down subsidiary8 Mar 2021, 10:46AM

Cipla Stock Price Analysis and Quick Research Report. Is Cipla an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Cipla and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 3460.31 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Cipla has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Cipla , the EPS growth was 6.44883053647508 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Cipla has OPM of 26.6789587197081 % which is a good sign for profitability.
     
  • ROE: Cipla have a average ROE of 13.2487186217313 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Cipla

X